AngioDynamics Divestiture Announcement: NAMIC Fluid Management BusinessApril 17, 2019

Forward-Looking Statements Notice Regarding Forward-Looking StatementsThis presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics’ expected future financial position, results of operations, cash flows, business strategy, budgets, projected costs, capital expenditures, products, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include the words such as “expects,” “reaffirms,” “intends,” “anticipates,” “plans,” “believes,” “seeks,” “estimates,” “optimistic,” or variations of such words and similar expressions, are forward-looking statements. Forward-looking statements in this presentation include, without limitation, projections for revenue, adjusted EPS and gross margin for fiscal years 2020, 2021 and 2022. These forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. Investors are cautioned that actual events or results may differ from AngioDynamics’ expectations. Factors that may affect the actual results achieved by AngioDynamics include, without limitation, the ability of AngioDynamics to develop its existing and new products, technological advances and patents attained by competitors, infringement of AngioDynamics’ technology or assertions that AngioDynamics’ technology infringes the technology of third parties, the ability of AngioDynamics to effectively compete against competitors that have substantially greater resources, future actions by the FDA or other regulatory agencies, domestic and foreign health care reforms and government regulations, results of pending or future clinical trials, overall economic conditions, the results of on-going litigation, challenges with respect to third-party distributors or joint venture partners or collaborators, the results of sales efforts, the effects of product recalls and product liability claims, changes in key personnel, the ability of AngioDynamics to execute on strategic initiatives, the effects of economic, credit and capital market conditions, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from group purchasing organizations and competition, the ability of AngioDynamics to integrate acquired businesses, as well as the risk factors listed from time to time in AngioDynamics’ SEC filings, including but not limited to its Annual Report on Form 10-K for the year ended May 31, 2018. AngioDynamics does not assume any obligation to publicly update or revise any forward-looking statements for any reason.In the United States, the NanoKnife System has received a 510(k) clearance by the Food and Drug Administration for use in the surgical ablation of soft tissue, and is similarly approved for commercialization in Canada, the European Union and Australia. The NanoKnife System has not been cleared for the treatment or therapy of a specific disease or condition.Notice Regarding Non-GAAP Financial MeasuresManagement uses non-GAAP measures to establish operational goals, and believes that non-GAAP measures may assist investors in analyzing the underlying trends in AngioDynamics’ business over time. Investors should consider these non-GAAP measures in addition to, not as a substitute for or as superior to, financial reporting measures prepared in accordance with GAAP. In this presentation, AngioDynamics has reported adjusted EBITDAS (income before interest, taxes, depreciation and amortization and stock-based compensation); adjusted net income; adjusted earnings per share and free cash flow. Management uses these measures in its internal analysis and review of operational performance. Management believes that these measures provide investors with useful information in comparing AngioDynamics’ performance over different periods. By using these non-GAAP measures, management believes that investors get a better picture of the performance of AngioDynamics’ underlying business. Management encourages investors to review AngioDynamics’ financial results prepared in accordance with GAAP to understand AngioDynamics’ performance taking into account all relevant factors, including those that may only occur from time to time but have a material impact on AngioDynamics’ financial results. Please see the tables that follow for a reconciliation of non-GAAP measures to measures prepared in accordance with GAAP.TrademarksAngioDynamics, the AngioDynamics logo, BioFlo, the BioFlo logo, NanoKnife, the NanoKnife logo, VenaCureEVLT, the VenaCureEVLT logo, AngioVac, the AngioVac logo, Solero, the Solero logo, Uni-Fuse, the Uni-Fuse logo, NAMIC, the NAMIC logo, OARtrac, Alatus, and ImmobiLoc are trademarks and/or registered trademarks of AngioDynamics, Inc., an affiliate or subsidiary. Endexo is a trademark and/or registered trademark of Interface Biologics. Habib is a trademark and/or registered trademark of Emcision. 2

Transaction Overview Transaction Value: $167.5 millionTransaction Structure: Cash free/debt freeAnticipated Closing: By end of FY19 contingent on HSR review and transition/ancillary agreementsNAMIC Assets Divested:Approximately $85mm in revenue (U.S. = $65mm, Int’l = $20mm)Approximately $30mm in EBITDAPrimary Glens Falls manufacturing facilityAll appropriate licenses and intellectual propertyFinancial Statement Impact: Treat NAMIC assets as discontinued operations and report pro forma resultsRemove all NAMIC assets (including intangibles and allocated goodwill) from balance sheet Anticipate new revolver-only credit facility of $125-$150mm commensurate with lower levels of EBITDA post transactionTotal available capital post-transaction of >$150 million 3

Executing on Our Strategy Accountability Focus Attractive Financial Profile Growth Drivers Revenue Growth 5%+ Capital Structure Flexibility Gross Margin Expansion Focused Portfolio Funding Investment Opportunities R&D + M&A to Accelerate Innovation NanoKnife AngioVac BioFlo InnovativeTechnologies + Attractive Markets + Ability to Win RadiaDyne Increased Capability in Clinical & Regulatory Execution Value Creation Operating Margin Improvement + + 4

Driving Future Growth Net cash balance of ~$74 million plus credit facility access will provide over $150 million of available capital to deploy Internal Investments:Oncology, NanoKnife PlatformThrombus Management, AngioVacSelective investments in Core and Vascular Access categories External Investments:M&A and Licensing for acquiring innovative assetsOpportunistic share repurchase and debt paydown Portfolio optimization will remain a priority; continued execution across entire product portfolioSustained focus on operational excellence and appropriate balance sheet stewardship 5

Portfolio Optimization and Strategy 6

Oncology Treatment Options Deliver disruptive innovations that improve quality of life during treatment, advance outcomes, extend life, and evolve toward curative therapy modalities Oncology Caregiver and Patient Journey

PancreaticCancer LungCancer ProstateCancer BrainCancer 57K CASES DIAGNOSED ANNUALLY8% 5-YEAR SURVIVAL RATEPMA PATHWAY CATEGORY B DESIGNATION 165K CASES DIAGNOSED ANNUALLY99% 5-YEAR SURVIVAL RATEUNDESIRABLE QUALITY OF LIFE OUTCOMESFOCAL THERAPY MOMENTUMRADIADYNE ADVANTAGES 234K CASES DIAGNOSED ANNUALLY20% 5-YEAR SURVIVAL RATEBIOPSY INTERVENTIONMICROWAVE PENETRATIONNxGEN IRE SOLUTION 24K CASES DIAGNOSED ANNUALLY35% 5-YEAR SURVIVAL RATENxGEN IRE SOLUTION & COMBINED MODALITIES American Cancer Society, Cancer Facts & Figures 2018 KEY DRIVERS NanoKnife as a Platform

FDA IDE APPROVAL - March 28, 2019STUDY DESIGN – One Study, Two ComponentsA Randomized Controlled Trial (RCT) at up to 15 sites A Real-World Evidence, Next-Generation Registry (RWE) at up to 30 sitesAngioDynamics expects each NanoKnife arm to consist of approximately 250 patients with an equal number of control patients.The primary endpoint of the Study is overall survival.Next-generation study with a Category B IDE Designation.Received central Institutional Review Board (IRB) approval.Initial enrollment expected June 2019. NanoKnife IDE Approval 9

MARKETS & OPPORTUNITIES: Oncology Radio Frequency Ablation MICROWAVE ABLATION, IRREVERSIBLE ELECTROPORATON Adaptive and IMMUNO-Oncology First Generation NxGen Platforms Stabilization Balloons andReal-Time Dosimetry Biosentry tract-sealant * Current Generation Ablative Oncology Solutions Radiation Therapy & Biopsy Solutions

MARKET & OPPORTUNITY: Thrombus Management LOW VOLUMEHIGH ASP GROWING MARKET ATTRACTIVE MKT. REVENUE LARGEADDRESSABLE PATIENT Pop. HIGH VOLUMELOW ASP S I M P L E C O M P L E X M O D E R A T E C a t h e t e r D I r e c t e d T h r o m b o l y s I s P E R C U T A N E O U S T H R O M B E C T O M Y L a r g e M a t e r I a l A s p I r a t I o n 48KPROCEDURES $640* +7.3%5YR CAGR Catheter Directed Thrombolysis Aspiration & Reinfusion $5.3M $12.5M Disease State FocusExpertise/AcumenThrombus Sales FootprintClinical Support TeamCall Point/SpecialtiesKOL RelationshipsPortfolio ConnectionCorporate Scale/InfrastructureR&D Pipeline M&A Capability COMPETENCIES Our market presence, resources and portfolio pipeline will enable us to increase our addressable market ~$640M* $56M ~$2.1B $17.8M ANGO Revenue(Uni-Fuse & AnioVac) ANGO Obtainable MKT Addressable Market(DVT, RH, PE) Total Market(DVT, RH, PE)

Secondary Areas of Investment Vascular Access Broad offering of peripherally inserted central catheters (PICCs), midline catheters, implantable ports, dialysis catheters and related accessories and supplies.Deliver, primarily, short-term drug therapies, such as chemotherapeutic agents and antibiotics, into the central venous system. Delivery to the circulatory system allows drugs to mix with a large volume of blood as compared to intravenous drug delivery into a superficial vessel. Core and EVLT Core Peripheral - Angiographic Catheters, Micro-Access, Drainage, GuidewiresMarket leading brands rooted, in quality, performance, selection and value, with broad procedural utilization across multiple specialties and care settings.Venous Therapies - VenaCure 1470 Pro Laser, Gold, Direct, OPS, Pvak, PacksMarket Leading Technology with proven Safety & Efficacy. Versatile Treatment used across CVI Classifications; Widely adopted with vast Payor Coverage. All-inclusive suite of Practice Development and Clinical Training programs. 12

Financial Metrics: FY20 through FY22 13

Revenue, Gross Margin and Adjusted EPS 4% - 6% 6% - 8% 7% - 9% -1.2% -1.5% 0% - 2%* * FY’19 Excludes 2 Mid Year Acquisitions Revenue Gross Margin % Adjusted EPS 50.4% 54% - 55% 60% - 61% ~400 Bps ~400 Bps ~200 Bps $0.70 - $0.80 $0.45 - $0.55 $0.25 - $0.30 $0.73 $0.74 $0.82 - $0.86 3-Yr CAGR: 12.5% 3-Yr CAGR: 55% - 60% 3-Yr CAGR: (0.5%) 3-Yr CAGR: 6 - 8% 14 Numbers for FY’19, FY’20, FY’21, and FY’22 represent estimates.

FY’2019 to FY’2020 Revenue Gross Margin % FY’19 Divestiture Discontinued Products Growth FY’20 VIT $204 - 205 ($84 - $85) ($5 - $6) $4 - $5 $116 - $118 VA $94 - $96 $0 - $2 $94 - $96 Onc $56 - $58 $14 - $16 $70 - $72 Total $354 - $359 $280 - $286 54% - 55% 58% - 59% ~ 400 bps ~ 30 bps ~ 30 bps Adjusted EPS ~ 20 bps OPEX % of Sales $354M - $359M $280M - $286M R&D % ~8.5% ~11% SG&A % ~32.5% ~43% 15 Numbers for FY’19, FY’20, FY’21, and FY’22 represent estimates.

Investment Decision Framework External InvestmentsMergers & AcquisitionsShare RepurchasesPaying Down Debt Internal InvestmentsResearch & DevelopmentSelling & MarketingManufacturing Return On InvestmentModel against hurdle rates and WACC to compare internal and external investment options Current Financial PositionSufficient liquidity to support investment needs Constant strategic review on where to invest excess cash Returns >WACC 16

Portfolio Optimization to Shape our Future Projected 3-Yr Outcomes Revenue6% - 8% CAGR Gross Margin60% - 61% Adjusted EPS55% - 60% CAGR Adjusted EBITDAS~$60M by 2022 Free Cash Flow~$50M+ by 2022 Invest in differentiated technologiesCreate leaner operationsImprove financial profileIncrease available capital to deploy Divestiture Rationale Divest non-strategic assetReduce manufacturing complexitySell NAMIC to owner with the right scale and long-term investment thesis 17